eHealth Initiative

ehidc.org

eHealth Initiative and Foundation (eHI) is a Washington DC-based, independent, non-profit organization whose mission is to drive improvements in the quality, safety, and efficiency of healthcare through information technology. eHI is a multi-stakeholder collaborative, convening executives from every group in healthcare, to discuss, identify, and share best practices that transform the delivery of healthcare. Working with its membership, eHI advocates for the use of health IT that is practical, sustainable, and addresses stakeholder needs, particularly those of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

news image

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Read More

Business Insights

ORSINI SPECIALTY PHARMACY SELECTED BY SANOFI AS A LIMITED DISTRIBUTION PARTNER FOR NEXVIAZYME®

Orsini Specialty Pharmacy | September 28, 2021

news image

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that Sanofi has selected it as a limited distribution partner for Nexviazyme® (avalglucosidase alfa-ngpt). Nexviazyme, an enzyme replacement therapy (ERT), is used for treating patients one year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). This progressive and debilitating muscle disorder impairs a person's abi...

Read More

COVID-19 ANTI-VIRAL DRUG REMDESIVIR EFFECTIVE ON MONKEYS AND PEOPLE

AsiaNews | April 18, 2020

news image

Washington (AsiaNews/Agencies) – The anti-viral drug remdesivir has proven effective in treating monkeys and people with COVID-19. Trial results have not yet been fully vetted by the scientific community, but they present good prospects for coronavirus patients. In a US study published yesterday by the National Institute of Infectious Diseases, two groups of six macaques were infected with the SARS-CoV-2, the coronavirus that causes COVID-19. One was treated with the antiviral drug remdesi...

Read More

Research, PHARMA TECH

POSITIVE RESULTS FOR AMBRX’S PROPRIETARY ANTI-PSMA ADC, ARX517, IN PROSTATE CANCER

Ambrx | February 21, 2023

news image

Ambrx Biopharma Inc., recently released positive preliminary results from its current Phase 1 trial, APEX-01 (NCT04662580), which is examining ARX517, Ambrx's patented anti-PSMA ADC, in patients with prostate cancer. Patients with advanced prostate cancer who have progressed on at least two prior FDA-approved treatments are enrolled in the Phase 1, first-in-human, open label dose escalation and dose expansion experiment known as APEX-01. In the US, APEX-01 is the only clinic...

Read More
news image

Business Insights

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Read More
news image

Business Insights

ORSINI SPECIALTY PHARMACY SELECTED BY SANOFI AS A LIMITED DISTRIBUTION PARTNER FOR NEXVIAZYME®

Orsini Specialty Pharmacy | September 28, 2021

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that Sanofi has selected it as a limited distribution partner for Nexviazyme® (avalglucosidase alfa-ngpt). Nexviazyme, an enzyme replacement therapy (ERT), is used for treating patients one year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). This progressive and debilitating muscle disorder impairs a person's abi...

Read More
news image

COVID-19 ANTI-VIRAL DRUG REMDESIVIR EFFECTIVE ON MONKEYS AND PEOPLE

AsiaNews | April 18, 2020

Washington (AsiaNews/Agencies) – The anti-viral drug remdesivir has proven effective in treating monkeys and people with COVID-19. Trial results have not yet been fully vetted by the scientific community, but they present good prospects for coronavirus patients. In a US study published yesterday by the National Institute of Infectious Diseases, two groups of six macaques were infected with the SARS-CoV-2, the coronavirus that causes COVID-19. One was treated with the antiviral drug remdesi...

Read More
news image

Research, PHARMA TECH

POSITIVE RESULTS FOR AMBRX’S PROPRIETARY ANTI-PSMA ADC, ARX517, IN PROSTATE CANCER

Ambrx | February 21, 2023

Ambrx Biopharma Inc., recently released positive preliminary results from its current Phase 1 trial, APEX-01 (NCT04662580), which is examining ARX517, Ambrx's patented anti-PSMA ADC, in patients with prostate cancer. Patients with advanced prostate cancer who have progressed on at least two prior FDA-approved treatments are enrolled in the Phase 1, first-in-human, open label dose escalation and dose expansion experiment known as APEX-01. In the US, APEX-01 is the only clinic...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us